Stock GMAB GENMAB A/S
Add to a list
To use this feature you must be a member
Log inSign up

Company Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen
Other stock markets
 10:59:56 2024-04-26 am EDT 		5-day change 1st Jan Change
1,954 DKK +2.04% Intraday chart for Genmab A/S -2.57% -9.30%
Apr. 16 Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug MT
Apr. 16 Genmab A/S Announces DARZALEX Sales Results for the First Quarter of 2024 CI

Business Summary

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:

- royalties (83.2%);

- income from research and development (12.4%);

- other (4.4%): primarily income from partnership agreement.

At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.

Denmark accounts for all net sales.

Number of employees: 2,204

Sales per Business

DKK in Million2022Weight2023Weight Delta
Antibody Therapeutics
100.0 %
14,595 100.0 % 16,474 100.0 % +12.87%

Sales per region

DKK in Million2022Weight2023Weight Delta
Denmark
97.4 %
14,595 100.0 % 16,053 97.4 % +9.99%
United States
2.3 %
0 0.0 % 380 2.3 % -
Japan
0.2 %
0 0.0 % 41 0.2 % -

Managers

Managers TitleAgeSince
Jan van de Winkel CEO
 Chief Executive Officer 63 98-12-31
Anthony Pagano DFI
 Director of Finance/CFO 46 06-12-31
Anthony Mancini COO
 Chief Operating Officer 53 20-03-22
Tahamtan Ahmadi CTO
 Chief Tech/Sci/R&D Officer 51 16-12-31
Marisol Peron IRO
 Public Communications Contact - 19-03-10
Christopher Cozic HRO
 Human Resources Officer 46 -
Judith Klimovsky PRN
 Corporate Officer/Principal 67 17-02-08
Martine van Vugt PRN
 Corporate Officer/Principal 71 00-12-31
Birgitte Stephensen LAW
 General Counsel 63 01-12-31

Members of the board

Members of the board TitleAgeSince
Deirdre Connelly CHM
 Chairman 63 16-12-31
Anders Gersel Pedersen BRD
 Director/Board Member 73 03-10-31
Rolf K. Hoffmann BRD
 Director/Board Member 63 15-12-31
Elizabeth O'Farrell BRD
 Director/Board Member 59 22-03-28
Pernille Erenbjerg BRD
 Director/Board Member 57 14-12-31
Paolo Augusto Paoletti BRD
 Director/Board Member 73 14-12-31
Mijke Zachariasse BRD
 Director/Board Member 51 19-03-28
Martin Schultz BRD
 Director/Board Member 49 21-12-31
Takahiro Hamatani BRD
 Director/Board Member 50 21-12-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 66,122,964 65,373,793 ( 98.87 %) 744,170 ( 1.125 %) 98.87 %

Shareholders

NameEquities%Valuation
Wellington Management Co. LLP
4.896 %
3,237,113 4.896 % 979 M kr
Global Opportunities (GO) Capital Asset Management BV
3.556 %
2,351,225 3.556 % 711 M kr
ATP Fondsmaeglerselskab A/S
2.318 %
1,532,909 2.318 % 463 M kr
GENMAB A/S
1.919 %
1,269,043 1.919 % 384 M kr
Jan van de Winkel
0.9082 %
600,497 0.9082 % 182 M kr
Industriens Pensionsforsikring A/S
0.7794 %
515,356 0.7794 % 156 M kr
Nykredit Bank A/S (Investment Management)
0.4817 %
318,516 0.4817 % 96 M kr
State Street Global Advisors Ltd.
0.2612 %
172,699 0.2612 % 52 M kr
Danske Bank A/S (Investment Management)
0.1986 %
131,323 0.1986 % 40 M kr
Sampension Administrationsselskab A/S
0.1744 %
115,344 0.1744 % 35 M kr
NameEquities%Valuation
AllianceBernstein LP
2.361 %
15,614,510 2.361 % 467 M kr
BlackRock Advisors LLC
0.6615 %
4,374,250 0.6615 % 131 M kr
Capital Research & Management Co. (International Investors)
0.6137 %
4,057,922 0.6137 % 121 M kr
Harding Loevner LP
0.4975 %
3,289,895 0.4975 % 98 M kr
Wellington Management Co. LLP
0.3583 %
2,369,331 0.3583 % 71 M kr
RBC Trust Co. Delaware Ltd.
0.2370 %
1,566,907 0.2370 % 47 M kr
Renaissance Technologies LLC
0.2261 %
1,494,800 0.2261 % 45 M kr
First Trust Advisors LP
0.1921 %
1,270,095 0.1921 % 38 M kr
Morgan Stanley Investment Management, Inc.
0.1647 %
1,089,097 0.1647 % 33 M kr
Wells Fargo Bank NA
0.1621 %
1,072,144 0.1621 % 32 M kr

Holdings

NameEquities%Valuation
GENMAB A/S
1.92%
 1,269,043 1.92% 383,665,874 $

Company contact information

Genmab A/S

Carl Jacobsens Vej 30 Valby

2500, Copenhagen

+45 70 20 27 28

http://www.genmab.com
address Genmab A/S(GMAB)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Ratings for Genmab A/S

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
1,954 DKK
Average target price
2,418 DKK
Spread / Average Target
+23.72%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
LEGEND BIOTECH CORPORATION Stock Legend Biotech Corporation
-24.71% 8.24B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. GMAB Stock
  4. Company Genmab A/S